Journal article
Lipoxins regulate the early growth response-1 network and reverse diabetic kidney disease
EP Brennan, M Mohan, A McClelland, C Tikellis, M Ziemann, A Kaspi, SP Gray, R Pickering, SM Tan, S Tasadaque Ali-Shah, PJ Guiry, A El-Osta, K Jandeleit-Dahm, ME Cooper, C Godson, P Kantharidis
Journal of the American Society of Nephrology | AMER SOC NEPHROLOGY | Published : 2018
Abstract
Background The failure of spontaneous resolution underlies chronic inflammatory conditions, including microvascular complications of diabetes such as diabetic kidney disease. The identification of endogenously generated molecules that promote the physiologic resolution of inflammation suggests that these bioactions may have therapeutic potential in the context of chronic inflammation. Lipoxins (LXs) are lipid mediators that promote the resolution of inflammation. Methods We investigated the potential of LXA4 and a synthetic LX analog (Benzo-LXA4) as therapeutics in a murine model of diabetic kidney disease, ApoE-/- mice treated with streptozotocin. Results Intraperitoneal injection of LXs at..
View full abstractGrants
Awarded by Juvenile Diabetes Research Foundation International
Funding Acknowledgements
E.P.B. was supported by an ELEVATE Irish Research Council Marie Curie Fellowship. This study was also supported by the National Health and Medical Research Council (NHMRC), the joint Juvenile Diabetes Research Foundation (JDRF)/National Health and Medical Research Foundation (NHMRC) Centres of Research Excellence (CRE) program, and in part by the Victorian Government's Operational Infrastructure Support Program and by Science Foundation Ireland and the Health Research Board awards (15/IA/3152; 15/US/B3130 and 11/PI/1206).